Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications

Rhonda M. Cooper-Dehoff, Sheron Wen, Amber L. Beitelshees, Issam Zineh, John G. Gums, Stephen T. Turner, Yan Gong, Karen Hall, Vishal Parekh, Arlene B. Chapman, Eric Boerwinkle, Julie A. Johnson

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose ≥100 mg/dL (impaired fasting glucose), triglyceride ≥150 mg/dL, high-density lipoprotein ≤40 mg/dL for men or ≤50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study (P<0.0001). Proportion with triglycerides ≥150 mg/dL increased from 33% at baseline to 46% at the end of study (P<0.01). New-onset diabetes mellitus occurred in 13 patients (6%) with and in 4 patients (2%) without abdominal obesity. Baseline levels of glucose, triglyceride, and high-density lipoprotein predicted adverse outcomes, and predictors for new-onset diabetes mellitus after monotherapy in those with abdominal obesity included hydrochlorothiazide strategy (odds ratio: 46.91 [95% CI: 2.55 to 862.40]), female sex (odds ratio: 31.37 [95% CI: 2.10 to 468.99]), and uric acid (odds ratio: 3.19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity.

Original languageEnglish (US)
Pages (from-to)61-68
Number of pages8
JournalHypertension
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2010

    Fingerprint

Keywords

  • Abdominal obesity
  • Atenolol
  • Hydrochlorothiazide
  • Hypertension
  • Metabolic syndrome
  • New-onset diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cooper-Dehoff, R. M., Wen, S., Beitelshees, A. L., Zineh, I., Gums, J. G., Turner, S. T., Gong, Y., Hall, K., Parekh, V., Chapman, A. B., Boerwinkle, E., & Johnson, J. A. (2010). Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension, 55(1), 61-68. https://doi.org/10.1161/HYPERTENSIONAHA.109.139592